Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis

Authors

  • sana imran Basic Medical Science Institute(BMSI), JPMC, Karachi
  • Moosa Khan Department of Pharmacology and Therapeutics, Basic Medical Science Institute, Jinnah Post Graduate Medical Center, Karachi, Pakistan
  • Mohammad Sair Department of Pharmacology and Therapeutics, Basic Medical Science Institute, Jinnah Post Graduate Medical Center, Karachi, Pakistan
  • Sarwat Jahan Department of Pharmacology and Therapeutics, Basic Medical Science Institute, Jinnah Post Graduate Medical Center, Karachi, Pakistan

Keywords:

Calcipotriol, betamethasone valerate, plaque psoriasis, psoriasis area severity index (PASI) parameter

Abstract

Objective:

Comparative role of topical Betamethasone valerate (0.1%) and topical Calcipotriol (0.005%) inthe treatment of plaque psoriasis.

Materials and Methods:

This 12 weeks research project was conducted in the Department of Pharmacology and Therapeutics, BMSI, JPMC, Karachi. Total 80 psoriatic (mild and moderate) patients were included in the study and they were divided into two groups, A and B; 40 patients in each group. The patients of group A were treated by Betamethasone valerate (0.1%) and the patients of group B were treated by Calcipotriol (0.005%). To observe any significant changes, the PASI parameter was applied at the end of study period.

Results:

Psoriasis severity improvement was monitored by Psoriasis Area Severity Index (PASI). As comparedto day 0, the mean PASI score changes in both treated groups i.e group A (Betamethasone valerate) and groupB (Calcipotriol) was highly significant at day 90 but the changes in mean PASI score was more marked ingroup B. In mild psoriasis, Calcipotriol causes 71.61% improvement in PASI score whereas Betamethasonevalerate causes 63.2% improvement. In moderate psoriasis, Calcipotriol causes 69.21% improvement in PASI score whereas Betamethasone valerate causes 60.44% improvement.

Conclusion:

Topical Calcipotriol was more effective in improvement of mild and moderate plaque psoriasis as compared to Betamethasone valerate in local population.

Downloads

Download data is not yet available.

Author Biography

sana imran, Basic Medical Science Institute(BMSI), JPMC, Karachi

M.Phil student, Department of Pharmacology & Therapeutics, BMSI, JPMC, Karachi

References

Bos JD, de Rie MA, Teunissen MB, Piskin G. Psoriasis deregulation of innate immunity. Br. J Dermatol 2005; 152:1098-1107.

Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 2004; 51:563-9.

Traub M, Marshall K. Psoriasis Pathophysiology, Conventional and Alternative Approaches to Treatment. Altern Med Rev 2007; 12:319-30.

Griffiths CE, Camp RD, Barker JN. Psoriasis. In: Burns DA, Breathnach SM, Cox N, Griffiths CE, eds. Rook’s Textbook of Dermatology. 7th ed. Oxford: Blackwell 2005; 35:1-36.

Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15:16-7.

Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K. Fitzpatrick's Dermatology in General Medicine. 6th ed. 2003.

"Psoriasis Update -Skin & Aging". Retrieved 2007-07- 28.

Dahri GM, Samdani AJ, Qazi N, Laghari MJ et al. To compare the role of calcipotriol alone versus combination with betamethasone in mild to moderate psoriasis. Sindh Univ Res J 2010; 42:69-72.

Ahmad GK, Choudhury AM, Khondker L, Khan MS. Comparative safety of topical calcipotriol (0.005%) versus topical corticosteroid (betamethasone 0.1%) in plaque type psoriasis. J Pak Assoc Dermatol 2013; 23:394-400.

Kragballe K, Austad A. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate twocompound product in the treatment of psoriasis. Br J Dermatol 2006; 6:1155-60.

Downloads

Published

2014-08-10

How to Cite

imran, sana ., Khan, M. ., Sair, M. ., & Jahan, S. . (2014). Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis. Journal of the Dow University of Health Sciences (JDUHS), 8(2), 59–61. Retrieved from https://mail.jduhs.com/index.php/jduhs/article/view/1452

Issue

Section

Original Articles